•
China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South Korea firm LG Chem Life Sciences, obtaining exclusive development and commercialization rights to the latter’s tigulixostat in China. Innovent Bio will pay LG Chem a USD 10 million upfront payment and is committed to USD…